Gilead Sciences
GILD
$109.98
Share price
-1.15%
Change (1 day)
71.12%
Change (1 year)
Categories
P/S ratio for Gilead Sciences (GILD)
P/S ratio as of June 2025 (TTM): 4.76
According to Gilead Sciences's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7.17. At the end of 2025 the company had a P/S ratio of 4.85.
P/S ratio history for Gilead Sciences from 2001 to 2025
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2025 | 4.85 | 18.78% |
| 2024 | 4.08 | 9.57% |
| 2023 | 3.72 | -5.68% |
| 2022 | 3.95 | 18.36% |
| 2021 | 3.33 | 12.73% |
| 2020 | 2.96 | -19.28% |
| 2019 | 3.66 | 1.12% |
| 2018 | 3.62 | 1.1% |
| 2017 | 3.58 | 15.47% |
| 2016 | 3.10 | -29.58% |
| 2015 | 4.41 | -22.34% |
| 2014 | 5.68 | -44.82% |
| 2013 | 10.3 | 78.9% |
| 2012 | 5.75 | 56.83% |
| 2011 | 3.67 | 0.28% |
| 2010 | 3.66 | -34.16% |
| 2009 | 5.55 | -36.37% |
| 2008 | 8.73 | -13.63% |
| 2007 | 10.1 | 2.11% |
| 2006 | 9.89 | -16.96% |
| 2005 | 11.9 | 0.5% |
| 2004 | 11.9 | -17.21% |
| 2003 | 14.3 | -0.5% |
| 2002 | 14.4 | -46.96% |
| 2001 | 27.1 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | 4.65 | -2.30% | 🇺🇸 USA |
 Vertex Pharmaceuticals VRTX | 10.5 | 121.31% | 🇺🇸 USA |
 AbbVie ABBV | 5.88 | 23.57% | 🇺🇸 USA |
 Illumina ILMN | 3.17 | -33.36% | 🇺🇸 USA |
 Biogen BIIB | 1.95 | -59.04% | 🇺🇸 USA |
 Pfizer PFE | 2.23 | -53.09% | 🇺🇸 USA |
 Johnson & Johnson JNJ | 4.23 | -11.13% | 🇺🇸 USA |
 Eli Lilly LLY | 15.0 | 215.27% | 🇺🇸 USA |
 Merck MRK | 3.21 | -32.58% | 🇺🇸 USA |